SynthesisBMC infectious diseases2026
The burden of sarcopenia in people living with HIV: a systematic review and meta-analysis across WHO regions.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia, characterized by progressive loss of skeletal muscle mass and function, represents an underrecognized comorbidity in people living with human immunodeficiency virus, and comprehensive prevalence data across WHO regions remain lacking.
objectiveTo estimate the prevalence of sarcopenia across WHO regions among people living with human immunodeficiency virus (HIV) and to identify demographic, clinical, and methodological factors associated with variations in reported prevalence.
methodsWe searched PubMed, Embase, Scopus, and Web of Science for observational studies published from 2000 onwards that reported the prevalence of sarcopenia in people living with human immunodeficiency virus. Prevalence estimates were pooled using a random-effects meta-analysis. Subgroup analyses examined variations by geographic region, diagnostic criteria, demographic characteristics, and virus-related factors. Publication bias was assessed using Egger's and Begg's tests.
resultsAcross 34 studies involving 7,216 participants in 15 countries, the pooled prevalence of sarcopenia was 16% (95% confidence interval: 12-21%). Substantial heterogeneity (93.6%) was observed. Prevalence estimates varied substantially by diagnostic criteria, ranging from 8% (EWGSOP2 2019) to 28% (Baumgartner criteria), highlighting the importance of standardised diagnostic approaches in future research. Geographic variation was evident, with Romania reporting the highest prevalence (34%). Meta-regression identified body mass index status as a significant moderator of variability in prevalence, and age above 50 years was associated with higher sarcopenia prevalence [odds ratio: 1.97 (1.30-2.98)]. No publication bias was detected. Sensitivity analysis demonstrated robustness. Evidence certainty was moderate.
conclusionsSarcopenia affects approximately one in six people living with HIV across the represented WHO regions, with considerable variation across diagnostic approaches and populations. While diagnostic harmonisation is needed to enable consistent epidemiological surveillance, clinical management of sarcopenia in PLHIV must adopt a personalised, risk-stratified approach that accounts for the considerable heterogeneity across individuals in age, body composition, ART history, and socioeconomic context. REGISTRATION: CRD 420,251,063,820. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.